Elanix Biotechnologies AG

  • WKN: A0WMJQ
  • ISIN: DE000A0WMJQ4
  • Land: Deutschland

Nachricht vom 17.03.2017 | 09:00

Elanix Biotechnologies AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Elanix Biotechnologies AG

17.03.2017 / 09:00
Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Notification of Major Holdings

1. Details of issuer
Elanix Biotechnologies AG
Domstr. 22
14482 Potsdam
Germany

2. Reason for notification
  Acquisition/disposal of shares with voting rights
  Acquisition/disposal of instruments
X Change of breakdown of voting rights
  Other reason:

3. Details of person subject to the notification obligation
Name: City and country of registered office:
Mr Prof. Wassim Raffoul

4. Names of shareholder(s)
holding directly 3% or more voting rights, if different from 3.
Lee-Ann Laurent-Applegate, Corinne Scaletta, Tomas Svoboda

5. Date on which threshold was crossed or reached
09 March 2017

6. Total positions
  % of voting rights attached to shares
(total of 7.a.)
% of voting rights through instruments
(total of 7.b.1 + 7.b.2)
total of both in %
(7.a. + 7.b.)
total number of voting rights of issuer
Resulting situation 50.00 % 0.00 % 50.00 % 6799200
Previous notification 65.25 % 0.00 % 65.25 % /

7. Notified details of the resulting situation
a. Voting rights attached to shares (Sec.s 21, 22 WpHG)
ISIN absolute in %
  direct
(Sec. 21 WpHG)
indirect
(Sec. 22 WpHG)
direct
(Sec. 21 WpHG)
indirect
(Sec. 22 WpHG)
DE000A0WMJQ4 172028 3227469 2.53 % 47.47 %
Total 3399497 50.00 %

b.1. Instruments according to Sec. 25 para. 1 No. 1 WpHG
Type of instrument Expiration or maturity date Exercise or conversion period Voting rights absolute Voting rights in %
%
    Total %

b.2. Instruments according to Sec. 25 para. 1 No. 2 WpHG
Type of instrument Expiration or maturity date Exercise or conversion period Cash or physical settlement Voting rights absolute Voting rights in %
%
      Total %

8. Information in relation to the person subject to the notification obligation
X Person subject to the notification obligation is not controlled and does itself not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer (1.).
  Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity:

Name % of voting rights (if at least held 3% or more) % of voting rights through instruments (if at least held 5% or more) Total of both (if at least held 5% or more)
 

9. In case of proxy voting according to Sec. 22 para. 3 WpHG

Date of general meeting:
Holding position after general meeting: % (equals voting rights)

10. Other explanatory remarks:
 



17.03.2017 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this
malformed JSON string, neither array, object, number, string or atom, at character offset 9 ["identify.exe: `%s' (..."] at E:\public_html\IRPages2\cgi-bin/0312/lib/user_functions_subs/getCompanyPictures.pl line 43
Content-type: text/html; charset=utf-8

Übersicht Indizes

GBC-Fokusbox

Hohes Kurspotenzial: „Attraktiver „Value-add“-Immobilienspezialist

Die Coreo AG führt derzeit eine Bezugsrechtskapitalerhöhung durch, in deren Rahmen ein Bruttoemissionserlös von bis zu 16 Mio. € angestrebt wird. Der Liquiditätserlös soll zum Erwerb von Gewerbe- und Wohnimmobilien für den Geschäftsbereich „Value Add“ verwendet werden. Derzeit, also pre money, verfügt die Gesellschaft über ein prognostiziertes NAV (auf Grundlage von GBC-Berechnungen) von 2,40 €. Für das laufende und kommende Geschäftsjahr rechnen wir mit einem spürbaren Ertrags- und Ergebnisanstieg. Neben der Steigerung von Mieterträgen sollte die Gesellschaft im nennenswerten Umfang Veräußerungserlöse erzielen sowie stille Reserven aufdecken. Auf Basis unseres DCF-Bewertungsmodells (post money) haben wir ein Kursziel von 3,10 € ermittelt. Auf Basis des aktuellen Kurses sowie des Platzierungspreises im Rahmen der Kapitalerhöhung von 1,60 € je Aktie lautet unserer Einschätzung KAUFEN.“

Aktuelle Research-Studie

Original-Research: Solutions 30 SE (von Sphene Capital GmbH): Buy Solutions 30 SE

19. Dezember 2018